A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• DNA repair mechanisms protect cells from damage, but also confer drug resistance in cancer.
• Poly(ADP-ribose) polymerases (PARP) are critical enzymes in DNA damage repair pathways.
• Tumor cells exploit PARP and defective homologous recombination (HR) for survival.

Purpose of the Study:

• To review the role of PARP in DNA repair.
• To discuss the mechanism and efficacy of PARP inhibitors in cancer therapy.
• To explore the chemistry of available PARP inhibitors.

Main Methods:

• Literature review of scientific articles and clinical data.
• Analysis of the role of PARP enzymes in DNA repair pathways.
• Examination of the therapeutic potential of PARP inhibitors.

Main Results:

• PARP enzymes are central to DNA repair, particularly in tumors with defective homologous recombination.
• PARP inhibitors induce apoptosis in cancer cells by blocking DNA repair.
• Clinical data indicates PARP inhibitors are effective beyond BRCA mutations, including in HR-deficient tumors.

Conclusions:

• PARP inhibitors represent a significant advancement in cancer treatment, especially for HR-dysfunctional tumors.
• Targeting PARP offers a viable strategy to overcome drug resistance and improve patient outcomes.
• Further investigation into PARP inhibitors holds great promise for future cancer therapies.